SCHEMBL5748169

SCHEMBL5748169

COc1cncnc1NS(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CCR4 P51679 20/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5737063 0.88 CCR4 (0.53) CCR4
SCHEMBL5957166 0.83 CCR4 (0.64) CCR4
SCHEMBL5748366 0.82 CCR4 (0.65) CCR4
SCHEMBL5737026 0.81 CCR4 (0.65) CCR4
SCHEMBL5737779 0.79 CCR4 (0.61) CCR4
SCHEMBL5736022 0.78 CCR4 (0.64) CCR4
SCHEMBL5736375 0.77 CCR4 (0.59) CCR4
SCHEMBL3294376 0.77 CCR4 (0.50) CCR4
SCHEMBL29369177 0.76 CCR4 (1.00) CCR4
SCHEMBL1731222 0.76 CCR4 (1.00) CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060189613-A1 Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) ASTRAZENECA AB (SE) 2006-08-24 — — US claimed
US-20060189613-A1 Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) ASTRAZENECA AB (SE) 2006-08-24 — — US disclosed
EP-1633723-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) AstraZeneca AB (SE) 2006-03-15 — — EP disclosed
WO-2004108690-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) ASTRAZENECA AB (SE) 2004-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189613-A1 Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) CCR4, CCR5, CCR2 CCR4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback